Triglav Skladi D.O.O. Takes $3.41 Million Position in Abbott Laboratories (NYSE:ABT)

Triglav Skladi D.O.O. acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 30,100 shares of the healthcare product maker's stock, valued at approximately $3,405,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Norges Bank bought a new position in Abbott Laboratories during the fourth quarter worth $2,373,461,000. T. Rowe Price Investment Management Inc. boosted its position in Abbott Laboratories by 383.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,358,698 shares of the healthcare product maker's stock worth $945,453,000 after purchasing an additional 6,628,310 shares during the period. Raymond James Financial Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $635,056,000. Capital International Investors boosted its position in Abbott Laboratories by 3.4% during the fourth quarter. Capital International Investors now owns 67,972,953 shares of the healthcare product maker's stock worth $7,688,160,000 after purchasing an additional 2,229,026 shares during the period. Finally, Northern Trust Corp boosted its position in Abbott Laboratories by 10.3% during the fourth quarter. Northern Trust Corp now owns 22,056,860 shares of the healthcare product maker's stock worth $2,494,851,000 after purchasing an additional 2,060,650 shares during the period. 75.18% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares of the company's stock, valued at approximately $9,625,404.96. The trade was a 55.90% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 95,278 shares of company stock valued at $12,745,859. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Price Performance

ABT traded down $0.19 on Friday, hitting $131.31. 6,144,711 shares of the stock were exchanged, compared to its average volume of 6,135,908. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The firm has a market capitalization of $228.46 billion, a price-to-earnings ratio of 17.16, a PEG ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The business has a 50-day moving average of $129.87 and a two-hundred day moving average of $124.62.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. Sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABT. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research report on Thursday, April 17th. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up previously from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Wall Street Zen cut shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Finally, Barclays boosted their target price on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $142.59.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.